Every one of those 1 sits in a single category, manufacturing. Clarity Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 3 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Copper-64
Every one of those 1 sits in a single category, manufacturing. Clarity Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 3 across the same-window beat baseline. At 6, the average consequence score sits below the same-window beat average of 6.8. We currently track 1 Supply Chain story that mention Copper-64, all published on March 25, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 25 Supply Chain stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Copper-64. Shared-story counts are live from our verified record — not editorial picks.
Clarity Pharmaceuticals has secured a large-scale manufacturing supply agreement with Theragenics for the production of copper-64. This strategic partnership addresses critical supply chain bottlenecks for radiopharmaceuticals, ensuring a reliable flow of isotopes for Clarity’s diagnostic and therapeutic clinical trials.